AP-T: Serotonin M levels at baseline can predict mucosal healing in Crohn's patients treated with infembite

BACKGROUND and Objective:studies have reported that serotonin M has been shown to be an up-and-down expression in Crohn's disease and has been considered a promising biomarker for predicting the response of inflammatory bowel disease patients to TNF treatmentThe purpose of this study is to verify this correlation and to assess the accuracy of serotonin M as a predictive indicator of the memlixix reaction to Crohn's diseasemethod sed
methods The researchers included patients who received infexisia monotherapy in the studyAll patients underwent a colonoscopy at week 54 to assess mucosal healingMeasurements of serum antimatomatomatoxm M and fecal calcitonin were measured after baseline and after 14 weeks of treatmentThe use of the Mann-Whitney test assessed the correlation between anti-cancer M and fecal calcin at baseline and at the 14th week and the healing of the mucous membrane at week 54The accuracy of the prediction of mucosal healing is evaluated by the area below the curve (AUC)results
In the queue of 45 patients, 27 showed mucosal healingAt baseline and 14 weeks, the level of serotonin M in patients with mucosal healing was significantly lower than in patients who did not reach this endpoint (P 0.001)The level of fecal calcin was also lower in the 14th week than in the non-responders (P 0.001)The baseline was significantly correlated with the serotonin M value serotonin in the 14th week (Spearman correlation coefficient: 0.92, P 0.001)The diagnostic accuracy of the anticancer M that predicts mucosal healing at baseline is greater than the fecal calcin (AUC - 0.51, P 0.001) conclusions
These results show that serotonin M can predict the therapeutic outcome of inflixil serotonin Compared with fecal calcin, the predictive power of anti-cancer M at baseline is considerable, thus indicating that serotonin M is a promising biomarker to drive Crohn's disease treatment options